# US 2026/0091004 A1 · Pharmaceutical injectable solution comprising dopamine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091004 A1
- Document ID: US20260091004A1
- Status: Published application
- Kind: A1
- Application number: 19/111,868
- Filed: 2023-09-13
- Published: 2026-04-02
- Earliest claimed: 2022-09-14
- Assignees: Inbrain Pharma; Universite De Lille; Centre Hospitalier Universitaire De Lille; Institut National de la Sante et de la Recherche Medicale
- Applicants: Inbrain Pharma; Universite De Lille; Centre Hospitalier Universitaire De Lille; Institut National De La Sante Et De La Recherche Medicale
- Inventors: Pascal ODOU; David DEVOS; Alexandre DEMAILLY; Matthieu FISICHELLA
- Web page: https://patentgrep.com/patent/US20260091004A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61P 25/16: Anti-Parkinson drugs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a pharmaceutical injectable solution comprising dopamine or a pharmaceutically acceptable salt thereof, preferably dopamine hydrochloride, dissolved in water for injection, wherein the solution has a pH between 3.0 and 5.5, and has an oxygen content equal to or lower than 0.008% (8 ppm), and uses thereof.

## Claims

### Claim 1

A pharmaceutical injectable solution comprising dopamine or a pharmaceutically acceptable salt thereof, dissolved in water for injection, wherein the solution has a pH between 3.0 and 5.5, and has an oxygen content equal to or lower than 0.008% (8 ppm).

### Claim 2 (depends on 1)

The pharmaceutical injectable solution according to claim 1, wherein the solution has a pH of about 4.0.

### Claim 3 (depends on 1)

The pharmaceutical injectable solution according to claim 1, wherein the solution contains dopamine or a pharmaceutically acceptable salt thereof in a concentration of at least 50 mg/mL.

### Claim 4 (depends on 1)

The pharmaceutical injectable solution according to claim 1, in which there is no addition of sodium chloride, especially when the pharmaceutically acceptable solution comprises a pharmaceutically acceptable salt which is dopamine hydrochloride.

### Claim 5 (depends on 1)

The pharmaceutical injectable solution according to claim 1, wherein the pharmaceutical injectable solution is free of preservative agent.

### Claim 6 (depends on 1)

A method of treatment of medical conditions linked to levels of dopamine, comprising a step of administering a therapeutically effective amount of the pharmaceutical injectable solution according to claim 1 to a subject in need thereof.

### Claim 7 (depends on 6)

The method of treatment of according to claim 6, wherein the medical condition linked to low levels of dopamine is selected from the group consisting of Parkinson's disease, Parkinson's disease syndromes, restless legs syndrome, depression, schizophrenia and attention deficit hyperactivity disorder (ADHD), neurodegeneration with brain iron accumulation and other vascular or degenerative brain diseases with doparesponsive parkinsonism, and genetic disorders affecting the enzymes of synthesis or metabolism.

### Claim 8 (depends on 6)

The method of treatment according to claim 6, wherein less than or equal to 3 mL of said pharmaceutical injectable solution is administered daily to the subject.

### Claim 9 (depends on 6)

The method of treatment according to claim 6, wherein at least 25 mg of dopamine is administered daily to the subject.

### Claim 10 (depends on 6)

The method of treatment according to claim 6, wherein the pharmaceutical injectable solution is administered into a brain ventricle.

### Claim 11 (depends on 6)

The method of treatment according to claim 6, wherein the pharmaceutical injectable solution is administered with an anaerobical pump.

### Claim 12 (depends on 11)

The method of treatment according to claim 11, wherein the pharmaceutical injectable solution is administered to the subject with an anaerobical pump at a flow rate between 0.04 mL/h and 0.125 mL/h.

### Claim 13 (depends on 6)

The method of treatment according to claim 6, wherein said solution is continuously administered to the subject with dose variations.

### Claim 14 (depends on 6)

The method of treatment according to claim 6, wherein said solution is administered with a predominant diurnal dose or with an exclusive diurnal dose.

### Claim 15 (depends on 6)

The method of treatment according to claim 6, wherein said solution is administered with the following dosage regimen:
a continuous diurnal dose,
optionally, a bolus administered on morning, and
optionally, at least a bolus when required, and/or
a continuous nocturnal dose lower than the diurnal dose.

### Claim 16 (depends on 6)

The method of treatment according to claim 6, wherein the pharmaceutical injectable solution is administered into the right lateral ventricle.

### Claim 17 (depends on 6)

The method of treatment according to claim 6, wherein the pharmaceutical injectable solution is administered at the entrance of the interventricular foramen.
